Logistically, it follows that tyrosine kinase receptors such as EGFR and others are promising candidate targets for cancer therapy and have led to the development of the tyrosine kinase inhibitors, such as the EGFR-targeting gefitinib and erlotinib. Here, NTRK1 is linked to cancer.